Business EconomyPosted at: Dec 13 2025 4:02AM


Ozempic ® - world’s most prescribed GLP-1is now available in India

Hyderabad, Dec 12 (UNI) Novo Nordisk, a global healthcare company, on Friday announced the launch of its once-weekly diabetes drug Ozempic® (injectable semaglutide) in India, marking a significant addition to the country’s treatment options for type 2 diabetes.
The therapy, a GLP-1 receptor agonist, is approved as an adjunct to diet and exercise for adults with uncontrolled type 2 diabetes mellitus (T2DM).
The introduction of Ozempic® comes at a critical time for India, which, according to WHO’s 2023–24 estimates, has 101 million people living with diabetes—about 11.4% of the population—along with 136 million individuals with prediabetes and 254 million with generalised obesity, the Denmark based healthcare company said in a release here.
The growing metabolic health burden has heightened the need for effective and evidence-based interventions.
Ozempic® has shown strong clinical outcomes, including substantial reductions in HbA1c levels and notable weight-loss benefits. It is suitable for adults with HbA1c levels of 7% or higher, including those with elevated cardiovascular risk or existing cardiovascular disease.
Clinical evidence also indicates a reduction in cardiovascular events and protection against the progression of chronic kidney disease, making the drug a comprehensive option for long-term diabetes management.
Calling the launch a major milestone, Vikrant Shrotriya, Managing Director of Novo Nordisk India, said the therapy brings global clinical trust and proven performance to Indian patients.
He emphasized that the once-weekly delivery through an easy-to-use pen device offers meaningful improvements in glycaemic control, weight management and cardiovascular and kidney outcomes.
Ozempic® works by mimicking the action of the natural hormone GLP-1, helping regulate blood sugar, reduce appetite and support weight loss in people with type 2 diabetes.
With a long-standing global safety profile and more than 38 million patient-years of clinical use, semaglutide was recently added to the World Health Organisation’s Model List of Essential Medicines, underscoring its growing importance in diabetes and obesity care.
The drug is now available in India in 0.25 mg, 0.5 mg and 1 mg strengths via the FlexTouch® pen, enabling doctors to tailor dosing to each patient’s needs for effective, sustained diabetes control.
Ozempic® is a GLP-1 receptor agonist that helps: Improve glycaemic control and reduce HbA1c; Regulate appetite and food intake by acting on areas of the brain that control hunger besides supporting weight loss in people with T2DM.
The use of this medication is strictly contingent upon a licensed healthcare provider’s prescription and clinical judgment.
Always consult your healthcare professional for medical advice and treatment options tailored to your individual needs, it said.
UNI KNR RN
Please log in to get detailed story.
Tags: #Ozempic ® - world’s most prescribed GLP-1is now available in India
More News

Kedaara Capital appoints Dr Hari Prasad as Operating Advisor

17 Jan 2026 | 6:57 PM

Hyderabad, Jan 17 (UNI) Kedaara Capital today announced the appointment of Dr. Hari Prasad as an Operating Advisor, strengthening the firm’s healthcare advisory capabilities.

see more..

Reliance Posts flat Q3 FY26 profit at Rs 18,645 cr, revenue up by 10 5 per cent

17 Jan 2026 | 5:37 PM

Mumbai, Jan 17 (UNI) Reliance Industries (RIL) has reported a consolidated net profit of Rs 18,645 crore in the third quarter of the financial year 2025-26 (Q3 FY26).

see more..

Mumbai to host first Global Economic Cooperation 2026 from February 17 to 19

17 Jan 2026 | 4:07 PM

New Delhi, Jan 17 (UNI) Senior policymakers, global corporate leaders, investors and heads of multilateral institutions from India and abroad will gather in Mumbai from February 17-19 for the inaugural Global Economic Cooperation 2026, a high-level, invitation-only forum aimed at redefining economic cooperation in an increasingly multipolar global order.

see more..

Growing self-confidence in “New India’s” youth is visible transformation: Piyush Goyal

17 Jan 2026 | 1:00 AM

New Delhi, Jan 16 (UNI) union Minister for Commerce and Industry Piyush Goyal today highlighted that one of the most visible transformations in a resurgent and new India is the growing self-confidence among the country’s youth.
While addressing the “Startup Pe Charcha” interaction at Bharat Mandapam, New Delhi, Minister Goyal highlighted that one of the most visible transformations in a resurgent and new India is the growing self-confidence among the country’s youth.

see more..

Koppert inaugurates expanded Mycorrhiza Production Facility in Hyderabad

16 Jan 2026 | 9:32 PM

Hyderabad, Jan 16 (UNI) Koppert Sustainable Solutions (India) Pvt. Ltd., a global leader in biological solutions for sustainable agriculture, on Friday announced the inauguration of its expanded ‘Mycorrhiza Production Facility’ at IDA Bollaram here on Friday, marking a significant milestone in its commitment to regenerative and environmentally responsible farming in India.

see more..